Printer Friendly

Genvec announces broad gene therapy patent.

GenVec, Inc. (Gaithersburg, MD; 240-632-5511), a leading biotechnology company in the development of gene-based pharmaceuticals, announced the company was issued a United States patent broadly covering replication-deficient adenovectors that are free of replication competent adenovirus. Such preparations are often referred to as "replication- competent-adenovirus-free" or "RCA-free" adenovectors, and provide significant advantages when used as tools for new product discovery and for therapeutic applications.

"The field of gene therapy has expended substantial efforts to create RCA-free adenovectors," said Dr. Paul H. Fischer, GenVec's president and chief executive officer. "We are pleased that GenVec received this broad patent that recognizes our pioneering efforts in this area. This patent adds an additional layer of proprietary protection for our growing product portfolio, that includes our therapeutic angiogenesis product candidate, BIOBYPASS angiogen, which is now in Phase II clinical studies for the treatment of coronary artery disease."

GenVec is a privately held biotechnology company focused on the development and commercialization of novel gene-based therapies for the treatment of major medical needs. The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates that address needs in the areas of cardiovascular disease, cancer and other therapeutic areas.
COPYRIGHT 2000 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Genvec announces broad gene therapy patent.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 1, 2000
Words:196
Previous Article:Isis Pharmaceuticals' Genetrove division and the R.W. Johnson Pharmaceutical Research Institute initiate antisense target validation program.
Next Article:Collateral announces expanded angiogenic gene research collaboration with New York University.
Topics:


Related Articles
Cell Genesys issued patent for adeno-associated viral gene therapy.
Genzyme receives broad patent covering gene therapy for Fabry disease.
Transgene receives patents covering homologous recombination technology in E. coli for fast generation of vectors.
Transkaryotic receives patent for gene targeting technology.
Genvec expands its angiogenesis technoogy for the prevention of blindness.
Transkaryotic awarded patent relating to production and delivery of proteins.
Transkaryotic announces victory in Genzyme patent litigation.
Transkaryotic reaches settlement in gene therapy patent interferences.
Ceregene announces issuance of patent for gene therapy.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters